The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis
Open accessAbstract
In June 1999, the Association of British Neurologists (ABN) first published guidelines for the use of the licensed multiple sclerosis (MS) disease-modifying treatments (at that time β-interferon and glatiramer acetate). The guidelines were revised in 2001 and have been periodically updated since then. In 2002, following the negative assessment of these treatments by the National Institute for Health and Care Excellence (NICE), the MS risk-sharing scheme started, in which patients eligible according to the 2001 ABN guidelines were provided with treatment funded through the UK National Health Service (NHS), and monitored annually for up to 10 years.1 Recruitment to the risk-sharing scheme cohort is complete. Pending a future final evaluation, the UK Department of Health's instruction to NHS funders remains in place: that patients who fulfil the ABN criteria should continue to receive treatment funded through the NHS. The British neurological community has fully accepted the risk-sharing scheme for prescribing β-interferon and glatiramer acetate. Approximately 70 ‘treating centres’ have recruited >5000 patients between 2002 and 2005, and these have been monitored annually for 10 years; many more patients have received these treatments since 2005. The ABN published revised guidelines in 2007, and then again in 2009, following the licensing of natalizumab and mitoxantrone. This 2015 revised guideline replaces former versions. It includes all newly approved or licensed treatments for MS and represents a consensus concerning their use. These guidelines will require future revision as other treatments receive approval (eg, daclizumab and ocrelizumab): we suggest they are reviewed after an interval of no longer than 12 months. The guideline is not intended to provide a complete description of the possible complications and monitoring of disease-modifying treatments in MS; we refer prescribing neurologists to the relevant summaries of product characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Cohen, J. A., Coles, A. J., Arnold, D. L., Confavreux, C., Fox, E. J., Hartung, H.-P., Havrdova, E., Selmaj, K. W., Weiner, H. L., Fisher, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61769-3 · Cited by 1,205
Self-citationKappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499
Self-citationInterferon beta-1b in secondary progressive MS: Results from a 3-year controlled study
The North American Study Group on Interferon beta-1b in Secondary Progressive MS (2004) · Neurology · doi:10.1212/01.wnl.0000146958.77317.3e · Cited by 423
Cited by
Brain health: time matters in multiple sclerosis
Giovannoni, G., Butzkueven, H., Dhib-Jalbut, S., Hobart, J., Kobelt, G., Pepper, G., Sormani, M. P., Thalheim, C., Traboulsee, A., & Vollmer, T. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.07.003 · Cited by 458
Self-citationHarding, K., Williams, O., Willis, M., Hrastelj, J., Rimmer, A., Joseph, F., Tomassini, V., Wardle, M., Pickersgill, T., Robertson, N., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.4905 · Cited by 366
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis
Muraro, P. A., Martin, R., Mancardi, G. L., Nicholas, R., Sormani, M. P., & Saccardi, R. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.81 · Cited by 304
Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis
Sucksdorff, M., Matilainen, M., Tuisku, J., Polvinen, E., Vuorimaa, A., Rokka, J., Nylund, M., Rissanen, E., & Airas, L. (2020) · Brain · doi:10.1093/brain/awaa275 · Cited by 142
Nylund, M., Sucksdorff, M., Matilainen, M., Polvinen, E., Tuisku, J., & Airas, L. (2022) · Brain Communications · doi:10.1093/braincomms/fcab301 · Cited by 48
Metadata
- Authors
- Scolding, N., Barnes, D., Cader, S., Chataway, J., Chaudhuri, A., Coles, A., Giovannoni, G., Miller, D., Rashid, W., Schmierer, K., Shehu, A., Silber, E., Young, C., & Zajicek, J.
- Venue
- Practical Neurology
- Publisher
- BMJ
- Published
- 2015-06-22
- Volume
- 15
- Issue
- 4
- Pages
- 273-279
- ISSN
- 1474-7758 (ISSN-L)
- 1474-7766
- OpenAlex
- W2138325312
- Cited by
- 222
- References
- 4
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. https://app.cochat.ai/papers/10.1136/practneurol-2015-001139
- The paper
- Scolding, N., Barnes, D., Cader, S., Chataway, J., Chaudhuri, A., Coles, A., Giovannoni, G., Miller, D., Rashid, W., Schmierer, K., Shehu, A., Silber, E., Young, C., & Zajicek, J. (2015). Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology. https://doi.org/10.1136/practneurol-2015-001139
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.